Glycated albumin and risk of cardiovascular diseases and mortality in patients with and without dialysis: A meta‐analysis
Authors' conclusion
High GA levels are associated with an increased risk of CVDs and mortality, regardless of dialysis status.
Study context
- Population
- Patients with and without dialysis in cohort studies (PubMed, Cochrane Library, Embase)
- Participants
- 80,024 patients17 cohort studies
- Comparison
- Higher vs lower glycated albumin levels
- Outcome
- CVD and mortality with higher GA
Methodological detailsrandom effects model, dose-response meta-regression (robust error meta-regression), 12 prospective and 5 retrospective cohorts
- Random effects model
- Dose-response meta-regression (robust error meta-regression)
- 12 prospective and 5 retrospective cohorts
Pooled result
As reported in the abstract
Higher GA vs Lower GAEstimate (95% CI)
CV mortality
HR 1.90(1.22–2.98)
All-cause mortality
HR 1.64(1.41–1.90)
Major adverse cardio-cerebral events
RR 1.41(1.17–1.71)
Coronary artery disease
OR 2.24(1.75–2.86)
Stroke
RR 1.72(1.24–2.38)
Further pooled results
Dose-response: Glycated albumin (GA) levels and risk of CV mortality, all-cause mortality and coronary artery disease
- Positive linear association with CV mortality
- P = 0.38
- Positive linear association with all-cause mortality
- P = 0.57
- Positive linear association with coronary artery disease
- P = 0.18
Subgroups by dialysis status: CV and all-cause mortality
- Difference between dialysis subgroups, CV mortality
- P = 0.02
- Difference between dialysis subgroups, all-cause mortality
- P = 0.03
- High GA associated with CV and all-cause mortality regardless of dialysis status
Original publication
Glycated albumin and risk of cardiovascular diseases and mortality in patients with and without dialysis: A meta‐analysis. Diabetes Obes Metab. Published 3 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →